RHHBY Roche Holdings Ltd AG (QX)

By Chris Wack

Syros Pharmaceuticals Inc. said it has entered into a clinical supply agreement with Roche Holding AG.

Under the agreement, Syros said it would supply SY-5609, its oral inhibitor of cyclin-dependent kinase 7, for a combination dosing cohort in Roche's ongoing Phase 1/1b trial, which is evaluating multiple targeted therapies or immunotherapy as single agents or in rational specified combinations in molecularly defined subsets of colorectal cancer patients.

Under the terms of the agreement, Roche would sponsor and conduct the Phase 1/1b study to evaluate the safety, tolerability and preliminary efficacy of the combination and will assume all costs associated with the study. In exchange for providing SY-5609, Syros would receive access to the data on SY-5609 in combination with atezolizumab. Syros retains all rights to SY-5609.

Syros said selective CDK7 inhibition has been shown to target two fundamental processes in cancer: transcription and cell cycle control. Research has shown that CDK7 inhibition induces DNA replication stress and genome instability in preclinical cancer models, triggering immune-response signaling, which is further enhanced by the addition of immune-checkpoint blockade.

Syros shares were up 18%, to $5.30, in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

August 05, 2021 07:45 ET (11:45 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.